share_log

百濟神州:截至2024年12月31日止年度全年業績公告

BEIGENE: ANNUAL RESULTS ANNOUNCEMENTFOR THE YEAR ENDED DECEMBER 31, 2024

HKEX ·  Mar 27 10:17

Summary by Moomoo AI

百濟神州2024年全年業績表現強勁,總收入達38.1億美元,同比增長55.0%。產品收入增長72.6%至37.8億美元,其中百悅澤全球銷售額達26.4億美元,同比增長104.9%;百澤安銷售額達6.2億美元,同比增長15.7%。毛利率達84.3%,經營虧損較上年收窄53.0%至5.68億美元。公司研發投入持續加大,全年研發費用增長9.8%至19.5億美元,銷售及管理費用增長21.4%至18.3億美元。截至2024年底,公司現金及現金等價物為26.4億美元,短期借款8.5億美元,長期借款1.7億美元。公司預計2025年將實現GAAP經營利潤和經營性現金流轉正。2024年公司在產品商業化和研發創新方面取得多項重要進展。美國FDA批准百澤安用於胃癌一線治療,歐盟批准其用於食管癌和胃癌一線治療。公司全球員工規模擴大至11,000人,其中研發人員超過1,100名,臨床團隊約3,700人,為未來持續創新和全球擴張奠定基礎。
百濟神州2024年全年業績表現強勁,總收入達38.1億美元,同比增長55.0%。產品收入增長72.6%至37.8億美元,其中百悅澤全球銷售額達26.4億美元,同比增長104.9%;百澤安銷售額達6.2億美元,同比增長15.7%。毛利率達84.3%,經營虧損較上年收窄53.0%至5.68億美元。公司研發投入持續加大,全年研發費用增長9.8%至19.5億美元,銷售及管理費用增長21.4%至18.3億美元。截至2024年底,公司現金及現金等價物為26.4億美元,短期借款8.5億美元,長期借款1.7億美元。公司預計2025年將實現GAAP經營利潤和經營性現金流轉正。2024年公司在產品商業化和研發創新方面取得多項重要進展。美國FDA批准百澤安用於胃癌一線治療,歐盟批准其用於食管癌和胃癌一線治療。公司全球員工規模擴大至11,000人,其中研發人員超過1,100名,臨床團隊約3,700人,為未來持續創新和全球擴張奠定基礎。
BEIGENE's overall performance in 2024 was strong, with total revenue reaching $3.81 billion, a year-on-year increase of 55.0%. Product revenue grew by 72.6% to $3.78 billion, with global sales of Baizean reaching $2.64 billion, a year-on-year increase of 104.9%; and Baizean's sales reaching $0.62 billion, a year-on-year increase of 15.7%. The gross margin reached 84.3%, and the operating loss narrowed by 53.0% to $0.568 billion compared to the previous year.The company's R&D investment continued to increase, with total R&D expenses rising by 9.8% to $1.95 billion, and sales and management expenses rising by 21.4% to $1.83 billion. As of the end of 2024, the company's cash and cash equivalents amounted to $2.64 billion, short-term borrowings were $0.85 billion, and long-term borrowings were $0.17 billion. The...Show More
BEIGENE's overall performance in 2024 was strong, with total revenue reaching $3.81 billion, a year-on-year increase of 55.0%. Product revenue grew by 72.6% to $3.78 billion, with global sales of Baizean reaching $2.64 billion, a year-on-year increase of 104.9%; and Baizean's sales reaching $0.62 billion, a year-on-year increase of 15.7%. The gross margin reached 84.3%, and the operating loss narrowed by 53.0% to $0.568 billion compared to the previous year.The company's R&D investment continued to increase, with total R&D expenses rising by 9.8% to $1.95 billion, and sales and management expenses rising by 21.4% to $1.83 billion. As of the end of 2024, the company's cash and cash equivalents amounted to $2.64 billion, short-term borrowings were $0.85 billion, and long-term borrowings were $0.17 billion. The company expects to achieve GAAP operating profit and positive operating cash flow in 2025.In 2024, the company made several important advancements in product commercialization and R&D innovation. The FDA in the USA approved Baizean for first-line treatment of gastric cancer, and the EU approved it for first-line treatment of esophageal and gastric cancer. The company's global workforce expanded to 11,000 people, including over 1,100 researchers and approximately 3,700 clinical team members, laying the foundation for continued innovation and global expansion in the future.
Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
Comment Comment · Views 269

Recommended

Statement

This page is machine-translated. Moomoo tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation.